Key Points
- BioNTech CEO Ugur Sahin sold 20,500 shares at an average price of $96.31, generating $1.97 million. The sale, conducted under a pre-arranged Rule 10b5-1 plan, reduced his direct holdings by 2.89% to 688,209 shares.
- Sahin also sold 149,500 shares in four earlier transactions from September 3–9, totaling approximately $15.08 million, indicating a series of planned insider sales.
- BioNTech reported a quarterly loss of $2.53 per share and revenue of $122.31 million, both below analyst expectations, while revenue fell 59.5% year over year. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $126.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 20,500 shares of the business's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00. Following the completion of the sale, the chief executive officer directly owned 688,209 shares in the company, valued at approximately $66,281,408.79. This trade represents a 2.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
- On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.
- On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00.
- On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.
BioNTech Trading Up 0.3%
Shares of BNTX stock opened at $96.73 on Friday. The company's fifty day simple moving average is $96.98 and its two-hundred day simple moving average is $95.38. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The stock has a market capitalization of $24.46 billion, a price-to-earnings ratio of -12.35 and a beta of 1.29.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech's revenue was down 59.5% on a year-over-year basis. During the same period in the previous year, the business earned ($1.60) earnings per share. As a group, analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.
Analyst Upgrades and Downgrades
BNTX has been the subject of several analyst reports. Sanford C. Bernstein restated a "market perform" rating on shares of BioNTech in a research note on Friday, June 5th. BMO Capital Markets cut BioNTech from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $128.00 to $105.00 in a research report on Tuesday. Citigroup lowered their price target on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a report on Wednesday, August 5th. Jefferies Financial Group restated a "buy" rating on shares of BioNTech in a research report on Monday, June 1st. Finally, UBS Group raised shares of BioNTech from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $117.00 to $135.00 in a research note on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and an average target price of $126.00.
View Our Latest Report on BNTX
Institutional Investors Weigh In On BioNTech
Institutional investors and hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC boosted its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company's stock valued at $26,000 after buying an additional 127 shares during the period. EFG International AG bought a new position in BioNTech in the 4th quarter worth about $29,000. Caitong International Asset Management Co. Ltd increased its stake in BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock worth $30,000 after acquiring an additional 260 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of BioNTech in the 2nd quarter valued at about $39,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after acquiring an additional 305 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.
The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
